COVID vaccine developer BioNTech sees profits rise

KIFI

Published November 9, 2021 6:18 AM

BERLIN (AP) — German pharmaceutical company BioNTech says its earnings grew again in the third quarter. The company partnered with Pfizer to develop the first widely used COVID-19 vaccine. It reported Tuesday a net profit of over 3.2 billion euros for the July-September period. That compares with a loss a year earlier of 210 million euros and a second-quarter profit of almost 2.8 billion euros. The company has said the windfall from its mRNA-based coronavirus vaccine will help it to develop drugs against cancer and other diseases.

Article Topic Follows: AP National Business

Jump to comments ↓

Associated Press

BE PART OF THE CONVERSATION

KIFI Local News 8 is committed to providing a forum for civil and constructive conversation.

Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here

If you would like to share a story idea, please submit it here.